EP Patent

EP1354880A1 — Halogen compounds having thrombopoietin receptor agonism

Assigned to Shionogi and Co Ltd · Expires 2003-10-22 · 23y expired

What this patent protects

Compounds of the general formula (III), prodrugs thereof, pharmaceutically acceptable salts of both, or solvates of them and exhibiting thrombopoietin receptor agonism: wherein R 9 is hydrogen atom, optionally substituted lower alkyl, or the like; R 10 , R 11 and R 12 are ea…

USPTO Abstract

Compounds of the general formula (III), prodrugs thereof, pharmaceutically acceptable salts of both, or solvates of them and exhibiting thrombopoietin receptor agonism: wherein R 9 is hydrogen atom, optionally substituted lower alkyl, or the like; R 10 , R 11 and R 12 are each independently optionally substituted alkyl, halogen atom, or the like; R 14 is each independently lower alkyl, halogen atom, or the like; n is an integer of 0 to 2; A 3 is a group represented by the formula: wherein R 13 is hydrogen atom or lower alkyl; T is oxygen atom or sulfur atom.

Drugs covered by this patent

Patent Metadata

Patent number
EP1354880A1
Jurisdiction
EP
Classification
—
Expires
2003-10-22
Drug substance claim
No
Drug product claim
No
Assignee
Shionogi and Co Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.